Bromosporine (BSP)

Bromosporine (BSP)

This compound is available from TocrisSigma and Cayman Chemical

overview

Bromodomains (BRDs) are protein interaction modules that read epigenetic marks recognizing ε-N-lysine acetylation motifs. The conserved BRD fold contains a deep, largely hydrophobic acetyllysine binding site, an attractive pocket for the development of small, pharmaceutically active molecules. BRDs have an important role in the targeting of chromatin-modifying enzymes to specific sites, including methyltransferases, HATs and transcription factors and regulate diverse biological processes from cell proliferation and differentiation to energy homeostasis and neurological processes.


Co-crystal structure of Bromosporine with BRD4(1)


Structure of Bromosporine

Proteins that contain BRDs have been implicated in the development of a large variety of diseases, including various cancers, inflammatory diseases and neurological diseases and the therapeutic potential of bromodomain inhibition has been shown in several of these diseases, such as HIV, cancer and inflammation. Bromosporine is a broad spectrum inhibitor for bromodomains and as such will be very useful in elucidating further biological roles of reader domains as well as a tool for the validation of functional assays.
properties

ethyl N-[6-(3-methanesulfonamido-4-methylphenyl)-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-yl]carbamate
Click here to download SDF file

Physical and chemical properties
Molecular weight404.44
Molecular formulaC17H20N6O4S
IUPAC Nameethyl N-[6-(3-methanesulfonamido-4-methylphenyl)-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-yl]carbamate
clogP0.78
PSA105.64
Storage2-8°C as powder. NB making aliquots rather than freeze-thawing is recommended
DissolutionSoluble in DMSO at least up to 50mM
SMILES:

CC1=C(NS(C)(=O)=O)C=C(C2=NN3C(C(NC(OCC)=O)=C2)=NN=C3C)C=C1

InChI:

InChI=1S/C17H20N6O4S/c1-5-27-17(24)18-15-9-14(21-23-11(3)19-20-16(15)23)12-7-6-10(2)13(8-12)22-28(4,25)26/h6-9,22H,5H2,1-4H3,(H,18,24)

InChIKey:

UYBRROMMFMPJAN-UHFFFAOYSA-N

selectivity profile

Differential Scanning Fluorimetry (DSF)

Thermal melting experiments were carried out using an Mx3005p Real Time PCR machine (Stratagene). Proteins were buffered in 10 mM HEPES pH 7.5, 500 mM NaCl and assayed in a 96-well plate at a final concentration of 2 µM in 20 µl volume. Bromosporine was added at a final concentration of 10 µM. SYPRO Orange (Molecular Probes) was added as a fluorescence probe at a dilution of 1:1000. Excitation and emission filters for the SYPRO-Orange dye were set to 465 nm and 590 nm, respectively. The temperature was raised with a step of 3 °C per minute from 25 °C to 96 °C and fluorescence readings were taken at each interval. The temperature dependence of the fluorescence during the protein denaturation process was approximated by the equation (displayed below) where ΔuG(T) is the difference in unfolding free energy between the folded and unfolded state, R is the gas constant and yF and yU are the fluorescence intensity of the probe in the presence of completely folded and unfolded protein respectively. The baselines of the denatured and native states were approximated by a linear fit. The observed temperature shifts, ΔTmobs, were recorded as the difference between the transition midpoints of sample and reference wells containing protein without ligand in the same plate and determined by non-linear least squares fit.

Selectivity
BromodomainThermal melt
10 µM
ΔTm
BRD2(1)4.4
BRD2(2)5.9
BRD3(1)5.3
BRD3(2)5.9
BRD4(1)6.9
BRD4(2)6.2
BRDT(1)7.3
BRDT(2)5.2
CECR28.3
PB1(5)0.4
TAF1(1)1.3
TAF1(2)5.2
TAF1L(1)0.9
TAF1L(2)0.9
BAZ2A1.2
TIF1α0.4
ATAD2-0.2
BRD93.9
CREBBP3.4
in vitro potency
cell based assay data
Potency in Cells
BRD4Accelerated FRAP recovery at 1 µM
CREBBPAccelerated FRAP recovery at 1 µM
TIF1αInactive at 10 µM
BAZ2AInactive at 10 µM
SMARCA2Inactive at 10 µM

Bromosporine shows moderate cytotoxicity in HeLa cells at 18 µM

references

 

Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia

Sarah Picaud, Katharina Leonards, Jean-Philippe Lambert, Oliver Dovey, Christopher Wells, Oleg Fedorov, Octovia Monteiro, Takao Fujisawa, Chen-Yi Wang, Hannah Lingard, Cynthia Tallant, Nikzad Nikbin, Lucie Guetzoyan, Richard Ingham, Steven V. Ley, Paul Brennan, Susanne Muller, Anastasia Samsonova, Anne-Claude Gingras, Juerg Schwaller, George Vassiliou, Stefan Knapp and Panagis Filippakopoulos. Science Advances  12 Oct 2016: Vol. 2, no. 10, e1600760. DOI: 10.1126/sciadv.1600760

pk properties
co-crystal structures
synthetic schemes

Scheme 1

Scheme 2

materials and methods